This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

InOncology.com

ELCC 2017

EUROPEAN LUNG CANCER CONFERENCE

This event has ended

At the 2017 European Lung Cancer Conference (ELCC), Boehringer Ingelheim hosted a satellite symposium entitled ‘Sharing our knowledge in NSCLC: case interchange of real-world experience.’ The event was chaired by Prof. Rolf Stahel, and included presentations from Dr Noemí Reguart, Prof. David Gandara and Dr Maximilian Hochmair.

 

Please see below for the presentations from this symposium as well as details of other BI activities at ELCC 2017.

 

The full ELCC 2017 programme can be found here.

ELCC symposium presentations:

Making the first decision: EGFR mutation-positive NSCLC in the advanced setting

Dr Noemi Reguart

Understanding choice in the treatment of squamous NSCLC: when should TKIs be considered?

Dr David Gandara

Antiangiogenic agents beyond first-line: matching patients with treatments

Dr Maximilian Hochmair

Chairperson

Prof. Rolf Stahel

Prof. Rolf Stahel

University Hospital Zürich
Zürich, Switzerland

Speakers

  • Dr Noemí Reguart

    Dr Noemí Reguart

    Hospital Clinic Barcelona, Barcelona, Spain
  • Prof. David Gandara

    Prof. David Gandara

    University of California, Davis, Sacramento, USA
  • Dr Maximilian Hochmair

    Dr Maximilian Hochmair

    Otto-Wagner-Spital, Vienna, Austria

Presentations

  • Saturday 6 May 2017

    Proffered Paper session

    • Targeted therapies and management of brain metastasis

      Afatinib* (A) plus cetuximab (C) in the treatment of patients (pts) with NSCLC: the story so far. (Presentation #86O).

      Smit et al

       

  • Saturday 6 May 2017

    Poster Display session

    • Advanced NSCLC

      Afatinib vs gefitinib for treatment-naïve patients with EGFRm+ NSCLC (LUX-Lung 7): analysis of time to treatment failure and impact of afatinib dose adjustment. (Presentation #100P)

      Yang et al.

       

      LUX-Lung 8 phase III trial: analysis of long-term response to second-line afatinib in patients with advanced squamous cell carcinoma (SCC) of the lung. (Presentation #102P)

      Yang et al.

       

      A non-interventional biomarker study in patients (pts) with non-small cell lung cancer (NSCLC) of adenocarcinoma histology who are treated with nintedanib** according to the approved label (LUME-BioNIS). (Presentation #139TiP)

      Reck et al.

    • Mesothelioma

      LUME-Meso: Randomised Phase II/III study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) followed by maintenance N or placebo (P) in chemo-naïve patients with malignant pleural mesothelioma (MPM). (Presentation #170TiP)

      Popat et al.

  • Sunday 7 May 2017

    Poster Discussion session

    • Targeted therapies and immunotherapies

      First-line afatinib for advanced EGFRm+ NSCLC: analysis of long-term responders (LTRs) in the LUX-Lung (LL) 3, 6 and 7 trials. (Presentation #92PD)

      Schuler et al.

       

      Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm+) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7). (Presentation #93PD)

      Corral et al.

Didn’t make ELCC? Find out upcoming oncology events.

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

*Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.